Paracetamol

PBAC's latest decision on Paracetamol: Recommended (2020). Considered for Fast effective temporary relief of pain and discomfort associated with headache, muscular aches, period pain, arthritis/osteoarthritis, toothache, migraine headache, cold & flu symptoms, tension headache, sinus pain/headache and backache. Reduces fever.

Eligible population

Patients intolerant to alternative therapy and undergoing palliative care requiring analgesia or fever relief

Therapy area

Pain

Line of therapy

Not applicable

Evidence base

Cost-minimisation

Primary endpoint

Cost-minimisation

Comparator

Panadol 24 (paracetamol suppositories 500 mg, 24 pack)

Economic model

Cost-minimisation

Budget impact

$13K

Eligible patients/year

1,794

ICER note

Cost-minimisation analysis; no ICER calculated as no clinical improvement demonstrated over comparator

Submission history

• Nov 2014: Not recommended · Restricted
• Jul 2020: Recommended · Restricted

Similar precedents

• Tapentadol
  similarity 0.71
• Oxycodone, tramadol, codeine, hydromorphone, morphine, tapentadol, buprenorphine, fentanyl
  similarity 0.70
• Methadone
  similarity 0.70
• Tramadol hydrochloride with paracetamol
  similarity 0.70
• Pregabalin
  similarity 0.67
• Oxycodone
  similarity 0.67